Campbells acted as Cayman Islands legal counsel to Keymed Biosciences Inc. 康諾亞生物醫藥科技有限公司 (“Keymed Biosciences”) in connection with its approximately HK$3.1 billion initial public offering and listing of its 58,264,500 shares (assuming the over-allotment option is not exercised) on the Main Board of the Hong Kong Stock Exchange.
O’Melveny & Myers and CYL & Partners, in association with Cooley HK, acted as Hong Kong legal counsel and AllBright Law Offices acted as PRC legal counsel to Keymed Biosciences. Kirkland & Ellis and Commerce & Finance Law Offices acted as Hong Kong legal counsel and PRC legal counsel, respectively, to the joint sponsors (including Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited and Huatai Financial Holdings (Hong Kong) Limited) and the underwriters (including Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited, Huatai Financial Holdings (Hong Kong) Limited and China Everbright Securities (HK) Limited).
Keymed Biosciences Inc is a China-based biotechnology company that focuses on the independent discovery and development of innovative biological therapies.
Cornerstone investors in Keymed Biosciences include Temasek, Hillhouse Capital, Invesco, and UBS Asset Management (Singapore), among others.
